Home » Newsletters » BioWorld Science

BioWorld Science

June 21, 2007

View Archived Issues

Pooled data show relief of fibromyalgia pain with pregabalin

Continued efficacy in systemic lupus erythematosus after 1 year with belimumab

Improvements in renal function with eprodisate in AA amyloidosis seen over 3 years

Mechanism of neuroprotective effect of NNZ-2256 studied in brain injury model

Gusperimus active in some patients with SLE-associated glomerulonephritis

Topiramate demonstrates potential in treating gliomas

Vegenics licenses antibodies against VEGF-C from CoGenesys

GlaxoSmithKline outlines planned launches in oncology

Novel compounds for autoimmune disorders claimed in recent patents

Enrollment completed in phase III trial of Yondelis for relapsed ovarian cancer

Geron increases stake in joint venture TA Therapeutics

Phase I study of HuCNS-SC advances into high-dose cohort

Positive preliminary findings from AVR-118 dermatological study

Canadian approval for Eloxatin in metastatic colorectal cancer

Algeta and Norwegian Radium Hospital extend cancer research agreement

AZD-2281 begins phase II trials for breast and ovarian cancers

BioSante and Pantarhei evaluate new oral contraceptive in phase II trial

Shire and Renovo sign licensing agreement for Juvista

IND submission for ALTU-237 in hyperoxalurias

Pfizer discontinues program for PF-3512676 + cytotoxic chemotherapy

Approvable letter for maraviroc

Once-daily Mikelan LA to launch in Japan

Favorable response by FDA to Epix's Vasovist appeal

Phase III ENRICH study of Efaproxyn fails to meet primary and secondary endpoints

Approvable letter for Intuniv in ADHD

Recent AiCuris and Ranbaxy patents disclose new antiinfective agents

Final U.S. approval for Exforge

Recent GSK and Ligand patents report novel therapeutic agents for thrombotic disorders

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...